Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis : results from a nationwide study in Sweden
(2020) In Alimentary Pharmacology and Therapeutics 52(4). p.655-668- Abstract
Background: There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC). Aim: To estimate the societal cost of actively treated CD and UC in Sweden. Methods: We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave. Results: The mean annual societal costs per working-age patient (18-64 years) with CD and... (More)
Background: There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC). Aim: To estimate the societal cost of actively treated CD and UC in Sweden. Methods: We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave. Results: The mean annual societal costs per working-age patient (18-64 years) with CD and UC were $22 813 (vs $7533 per comparator) and $14 136 (vs $7351 per comparator) respectively. In patients aged ≥65 years, the mean annual costs of CD and UC were $9726 and $8072 vs $3875 and $4016 per comparator respectively. The majority of cost for both CD (56%) and UC (59%) patients originated from productivity losses. Higher societal cost of working-age CD patients as compared to UC patients was related to greater utilisation of anti-TNF (22.2% vs 7.4%) and increased annual disability pension (44 days vs 25 days). Among incident CD and UC patients, the mean total cost over the first year per patient was over three times higher than comparators. Conclusion: In Sweden, the societal cost of incident and prevalent CD and UC patients was consistently two to three times higher than the general population.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2020-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Alimentary Pharmacology and Therapeutics
- volume
- 52
- issue
- 4
- pages
- 14 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85087460640
- pmid:32902894
- ISSN
- 0269-2813
- DOI
- 10.1111/apt.15889
- language
- English
- LU publication?
- yes
- id
- 70f80309-8dcc-4bc0-8011-ad043eec3743
- date added to LUP
- 2020-07-18 17:41:22
- date last changed
- 2024-12-26 14:39:18
@article{70f80309-8dcc-4bc0-8011-ad043eec3743,
abstract = {{<p>Background: There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC). Aim: To estimate the societal cost of actively treated CD and UC in Sweden. Methods: We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave. Results: The mean annual societal costs per working-age patient (18-64 years) with CD and UC were $22 813 (vs $7533 per comparator) and $14 136 (vs $7351 per comparator) respectively. In patients aged ≥65 years, the mean annual costs of CD and UC were $9726 and $8072 vs $3875 and $4016 per comparator respectively. The majority of cost for both CD (56%) and UC (59%) patients originated from productivity losses. Higher societal cost of working-age CD patients as compared to UC patients was related to greater utilisation of anti-TNF (22.2% vs 7.4%) and increased annual disability pension (44 days vs 25 days). Among incident CD and UC patients, the mean total cost over the first year per patient was over three times higher than comparators. Conclusion: In Sweden, the societal cost of incident and prevalent CD and UC patients was consistently two to three times higher than the general population.</p>}},
author = {{Khalili, Hamed and Everhov, Åsa H. and Halfvarson, Jonas and Ludvigsson, Jonas F. and Askling, Johan and Myrelid, Pär and Söderling, Jonas and Olen, Ola and Neovius, Martin and Olsson, Malin and Hjortswang, Henrik and Bengtsson, Jonas and Strid, Hans and Andersson, Marie and Jäghult, Susanna and Eberhardsson, Michael and Nordenvall, Caroline and Björk, Jan and Fagerberg, Ulrika and Rejler, Martin and Grip, Olof}},
issn = {{0269-2813}},
language = {{eng}},
number = {{4}},
pages = {{655--668}},
publisher = {{Wiley-Blackwell}},
series = {{Alimentary Pharmacology and Therapeutics}},
title = {{Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis : results from a nationwide study in Sweden}},
url = {{http://dx.doi.org/10.1111/apt.15889}},
doi = {{10.1111/apt.15889}},
volume = {{52}},
year = {{2020}},
}